Drugs / Symbiter-Omega
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04201938 | Feb → Mar 2018 | abdominal obesity-metabolic syndrome, obesity disorder, type 2 diabetes mellitus | Bogomolets National Medical University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Symbiter-Omega | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04201938 ↗ |
| Modality | Other / unclassified | “Symbiter-Omega contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains” NCT04201938 ↗ |